Naltrexone utility in depressed alcoholics

Ihsan M Salloum, Jack R. Cornelius, Michael E. Thase, Dennis C. Daley, Levent Kirisci, Crystal Spotts

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

The aim of this open-label pilot study was to evaluate the utility of naltrexone (50 mg per day) in decreasing alcohol use and to examine its impact on depressive symptoms among depressed alcoholics who have failed to abstain from alcohol use despite treatment with a selective serotonin reuptake inhibitor (SSRI). Fourteen ambulatory care patients, aged 18 to 65 years, with DSM-III-R comorbid diagnoses of alcohol dependence and major depressive disorder, who failed to abstain despite treatment with an antidepressant medication were enrolled in the study. Patients were followed for 12 weeks with weekly assessment of drinking behavior, depressive symptoms, functioning, alcohol craving, and side effects. The results of this study indicated a significant decrease in alcohol use and in urges to drink alcohol in the presence of the usual triggers. There was also a trend suggesting improvement in depressive symptoms and overall functioning. Naltrexone was well tolerated, with mild side effects reported at the onset of treatment.

Original languageEnglish
Pages (from-to)111-115
Number of pages5
JournalPsychopharmacology Bulletin
Volume34
Issue number1
StatePublished - Apr 29 1998
Externally publishedYes

Fingerprint

Naltrexone
Alcoholics
Alcohols
Depression
Drinking Behavior
Major Depressive Disorder
Serotonin Uptake Inhibitors
Ambulatory Care
Diagnostic and Statistical Manual of Mental Disorders
Antidepressive Agents
Alcoholism
Therapeutics

Keywords

  • Depressed alcoholics
  • Dual diagnosis
  • Naltrexone
  • Treatment

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Salloum, I. M., Cornelius, J. R., Thase, M. E., Daley, D. C., Kirisci, L., & Spotts, C. (1998). Naltrexone utility in depressed alcoholics. Psychopharmacology Bulletin, 34(1), 111-115.

Naltrexone utility in depressed alcoholics. / Salloum, Ihsan M; Cornelius, Jack R.; Thase, Michael E.; Daley, Dennis C.; Kirisci, Levent; Spotts, Crystal.

In: Psychopharmacology Bulletin, Vol. 34, No. 1, 29.04.1998, p. 111-115.

Research output: Contribution to journalArticle

Salloum, IM, Cornelius, JR, Thase, ME, Daley, DC, Kirisci, L & Spotts, C 1998, 'Naltrexone utility in depressed alcoholics', Psychopharmacology Bulletin, vol. 34, no. 1, pp. 111-115.
Salloum IM, Cornelius JR, Thase ME, Daley DC, Kirisci L, Spotts C. Naltrexone utility in depressed alcoholics. Psychopharmacology Bulletin. 1998 Apr 29;34(1):111-115.
Salloum, Ihsan M ; Cornelius, Jack R. ; Thase, Michael E. ; Daley, Dennis C. ; Kirisci, Levent ; Spotts, Crystal. / Naltrexone utility in depressed alcoholics. In: Psychopharmacology Bulletin. 1998 ; Vol. 34, No. 1. pp. 111-115.
@article{f7865628d6fe4ec8a0d61933bb776269,
title = "Naltrexone utility in depressed alcoholics",
abstract = "The aim of this open-label pilot study was to evaluate the utility of naltrexone (50 mg per day) in decreasing alcohol use and to examine its impact on depressive symptoms among depressed alcoholics who have failed to abstain from alcohol use despite treatment with a selective serotonin reuptake inhibitor (SSRI). Fourteen ambulatory care patients, aged 18 to 65 years, with DSM-III-R comorbid diagnoses of alcohol dependence and major depressive disorder, who failed to abstain despite treatment with an antidepressant medication were enrolled in the study. Patients were followed for 12 weeks with weekly assessment of drinking behavior, depressive symptoms, functioning, alcohol craving, and side effects. The results of this study indicated a significant decrease in alcohol use and in urges to drink alcohol in the presence of the usual triggers. There was also a trend suggesting improvement in depressive symptoms and overall functioning. Naltrexone was well tolerated, with mild side effects reported at the onset of treatment.",
keywords = "Depressed alcoholics, Dual diagnosis, Naltrexone, Treatment",
author = "Salloum, {Ihsan M} and Cornelius, {Jack R.} and Thase, {Michael E.} and Daley, {Dennis C.} and Levent Kirisci and Crystal Spotts",
year = "1998",
month = "4",
day = "29",
language = "English",
volume = "34",
pages = "111--115",
journal = "Psychopharmacology Bulletin",
issn = "0048-5764",
publisher = "MedWorks Media LLC",
number = "1",

}

TY - JOUR

T1 - Naltrexone utility in depressed alcoholics

AU - Salloum, Ihsan M

AU - Cornelius, Jack R.

AU - Thase, Michael E.

AU - Daley, Dennis C.

AU - Kirisci, Levent

AU - Spotts, Crystal

PY - 1998/4/29

Y1 - 1998/4/29

N2 - The aim of this open-label pilot study was to evaluate the utility of naltrexone (50 mg per day) in decreasing alcohol use and to examine its impact on depressive symptoms among depressed alcoholics who have failed to abstain from alcohol use despite treatment with a selective serotonin reuptake inhibitor (SSRI). Fourteen ambulatory care patients, aged 18 to 65 years, with DSM-III-R comorbid diagnoses of alcohol dependence and major depressive disorder, who failed to abstain despite treatment with an antidepressant medication were enrolled in the study. Patients were followed for 12 weeks with weekly assessment of drinking behavior, depressive symptoms, functioning, alcohol craving, and side effects. The results of this study indicated a significant decrease in alcohol use and in urges to drink alcohol in the presence of the usual triggers. There was also a trend suggesting improvement in depressive symptoms and overall functioning. Naltrexone was well tolerated, with mild side effects reported at the onset of treatment.

AB - The aim of this open-label pilot study was to evaluate the utility of naltrexone (50 mg per day) in decreasing alcohol use and to examine its impact on depressive symptoms among depressed alcoholics who have failed to abstain from alcohol use despite treatment with a selective serotonin reuptake inhibitor (SSRI). Fourteen ambulatory care patients, aged 18 to 65 years, with DSM-III-R comorbid diagnoses of alcohol dependence and major depressive disorder, who failed to abstain despite treatment with an antidepressant medication were enrolled in the study. Patients were followed for 12 weeks with weekly assessment of drinking behavior, depressive symptoms, functioning, alcohol craving, and side effects. The results of this study indicated a significant decrease in alcohol use and in urges to drink alcohol in the presence of the usual triggers. There was also a trend suggesting improvement in depressive symptoms and overall functioning. Naltrexone was well tolerated, with mild side effects reported at the onset of treatment.

KW - Depressed alcoholics

KW - Dual diagnosis

KW - Naltrexone

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0031902430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031902430&partnerID=8YFLogxK

M3 - Article

C2 - 9564207

AN - SCOPUS:0031902430

VL - 34

SP - 111

EP - 115

JO - Psychopharmacology Bulletin

JF - Psychopharmacology Bulletin

SN - 0048-5764

IS - 1

ER -